Circulation 2025/4/1
A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure.
Mentions
Extended reach
Total likes
Video views
Mentions per month
Apr 2025 – Jun 2025Where it's discussed
-
X / Twitter87 posts
-
News4 articles
-
Bluesky2 posts
-
YouTube2 videos
-
Reddit2 posts
-
Blogs2 articles
AI synopsis
What people are saying
Many discussions highlight key findings from the publication, such as comments asserting that 'routine thoracentesis showed no significant benefit' and 'this study suggests a rather limited role for the procedure.' The tone is generally serious and analytical; phrases like 'higher congratulations to the authors' convey a positive reception of the research while also underscoring its relevance in clinical settings. This choice of words illustrates the community's recognition of the evidence's potential to reshape treatment approaches.
The majority of discussions reflect a consensus that routine thoracentesis may not be beneficial, showing moderate agreement with the study's findings.
The posts indicate a strong curiosity about the results and their implications for clinical practice, suggesting that the topic resonates with many.
While there are clear references to the study, the depth of engagement varies, with some discussions providing detailed commentary while others are more superficial.
Users perceive this study as having significant implications for future treatment protocols and clinical decisions in acute heart failure management.
Abstract in brief
- TAP-IT studied the impact of combining thoracentesis with standard treatment for patients suffering from acute heart failure and noticeable pleural effusion.
- Patients with specific criteria were randomized into two groups: one receiving thoracentesis plus standard treatment and the other receiving only standard treatment.
- Results showed minimal differences in days alive out of the hospital and overall mortality rates between the two groups, suggesting that routine thoracentesis may not significantly improve outcomes for these patients.
Top posts
Most liked on X and Bluesky心不全の胸水、利尿薬でゆっくり引くなんて焦ったいことせずに、抜いちゃえばいいぢゃん、っていうRCT。こういう素朴な臨床疑問好きです。結果は利尿薬のみと変わらずでプラクティスは変えず。でも心不全の胸水にドレーン入れているのをバイト先で見たことはある。。 https://t.co/oRar4pAcKP
急性心不全に胸水穿刺を行うか否かのRCT!protocol paperも出てて、気になっていたけど、結果出たんですね。 ✅胸水穿刺は非入院期間における生存日数を改善せず #昨日みんな話題にしてた https://t.co/yUfjouQgpu
https://t.co/QHLboxkGpQ Highest congratulations to the authors, Dr. Signe Glargaard et al
Finally! TAP-IT putting this long-standing, overused procedure under the spotlight. I’ve been side-eyeing it for years—and staying clear. Glad to see the data catching up. Kudos to authors. #signeglargaard #CardioTwitter #EvidenceMatters https://t.co/rn6p6KZvuN https://t.co/AlgDO19XUg
Routine thoracentesis in acute HF with pleural effusion doesn’t improve DAOH, mortality, or shorten hospital stay @mortschou @signeglargaard https://t.co/p9RC3TwPfM https://t.co/FIMxGmngEH
All mentions
Exploring Fluid Management Strategies in Heart Failure
Dr. Roland van Kimmenade and Dr. Signe Glargaard discuss novel evidence on fluid management in heart failure, focusing on their FRESH-UP and TAP-IT studies. These studies investigate the effects of fluid intake and…
Tirzepatide's Impact on Heart Failure and Obesity Outcomes
This podcast discusses the TAPIT STRIDE FreshUP and SINGLE SHOT CHAMPION trials, focusing on the effects of tirzepatide in heart failure management. The trials indicate that tirzepatide may lead to fewer cardiovascular…
https://t.co/stMsyEyBYb Well it really doesnt work so we should stop draining them and causing pain only for it to reaccumulate when we remove the drain
RT @qqqjunpei: Circulation 2025/4/1
A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure | Circulation https://t.co/epEsOxmr3w
A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure
RT @gabi_puchepalao: ACCESO gratis : Glargaard S et al. Circulation 2025. DOI: https://t.co/vtF2iFinM4
【DrゆみのWeekly Journal Scan】 *急性心不全に対する胸水穿刺 from Circulation* https://t.co/ycfNjhAvTu
*急性心不全に対する胸水穿刺 from Circulation* https://t.co/ycfNjhAvTu
RT @gabi_puchepalao: ACCESO gratis : Glargaard S et al. Circulation 2025. DOI: https://t.co/vtF2iFinM4
RT @gabi_puchepalao: ACCESO gratis : Glargaard S et al. Circulation 2025. DOI: https://t.co/vtF2iFinM4
RT @gabi_puchepalao: ACCESO gratis : Glargaard S et al. Circulation 2025. DOI: https://t.co/vtF2iFinM4
ACCESO gratis : Glargaard S et al. Circulation 2025. DOI: https://t.co/vtF2iFinM4
RT @kuroda_shunsuke: 急性心不全に胸水穿刺を行うか否かのRCT!protocol paperも出てて、気になっていたけど、結果出たんですね。 ✅胸水穿刺は非入院期間における生存日数を改善せず #昨日みんな話題にしてた https://t.co/yUfjou…
RT @kuroda_shunsuke: 急性心不全に胸水穿刺を行うか否かのRCT!protocol paperも出てて、気になっていたけど、結果出たんですね。 ✅胸水穿刺は非入院期間における生存日数を改善せず #昨日みんな話題にしてた https://t.co/yUfjou…
A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure | Circulation https://t.co/IhJ2786Mwm
RT @kuroda_shunsuke: 急性心不全に胸水穿刺を行うか否かのRCT!protocol paperも出てて、気になっていたけど、結果出たんですね。 ✅胸水穿刺は非入院期間における生存日数を改善せず #昨日みんな話題にしてた https://t.co/yUfjou…
RT @kuroda_shunsuke: 急性心不全に胸水穿刺を行うか否かのRCT!protocol paperも出てて、気になっていたけど、結果出たんですね。 ✅胸水穿刺は非入院期間における生存日数を改善せず #昨日みんな話題にしてた https://t.co/yUfjou…
RT @kuroda_shunsuke: 急性心不全に胸水穿刺を行うか否かのRCT!protocol paperも出てて、気になっていたけど、結果出たんですね。 ✅胸水穿刺は非入院期間における生存日数を改善せず #昨日みんな話題にしてた https://t.co/yUfjou…
RT @kuroda_shunsuke: 急性心不全に胸水穿刺を行うか否かのRCT!protocol paperも出てて、気になっていたけど、結果出たんですね。 ✅胸水穿刺は非入院期間における生存日数を改善せず #昨日みんな話題にしてた https://t.co/yUfjou…
RT @kuroda_shunsuke: 急性心不全に胸水穿刺を行うか否かのRCT!protocol paperも出てて、気になっていたけど、結果出たんですね。 ✅胸水穿刺は非入院期間における生存日数を改善せず #昨日みんな話題にしてた https://t.co/yUfjou…
RT @kuroda_shunsuke: 急性心不全に胸水穿刺を行うか否かのRCT!protocol paperも出てて、気になっていたけど、結果出たんですね。 ✅胸水穿刺は非入院期間における生存日数を改善せず #昨日みんな話題にしてた https://t.co/yUfjou…
急性心不全に胸水穿刺を行うか否かのRCT!protocol paperも出てて、気になっていたけど、結果出たんですね。 ✅胸水穿刺は非入院期間における生存日数を改善せず #昨日みんな話題にしてた https://t.co/yUfjouQgpu
A Randomized Controlled Trial of Thoracentesis in Acute HF strategy of upfront routine thoracentesis in addition to standard medical therapy did not increase days alive out of the hospital for 90 days, all-cause mortality, or duration of index admission https://t.co/EKJO6CK8vP https://t.co/5eCj3W8Aev
RT @CircAHA: Routine thoracentesis in acute HF with pleural effusion doesn’t improve DAOH, mortality, or shorten hospital stay @mortschou…
https://t.co/bh6TZSDGos
RT @MarkusAtHome: A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure (TAP-IT) by Drs. @signeglargaard, Thune et al. ht…
RT @qqqjunpei: Circulation 2025/4/1
RT @qqqjunpei: Circulation 2025/4/1
A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure (TAP-IT) by Drs. Glargaard, Thune et al. www.ahajournals.org/doi/10.1161/... Routine thoracentesis in addition to standard medical therapy showed no significant benefit!
A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure (TAP-IT) by Drs. @signeglargaard, Thune et al. https://t.co/iEYMpz9AaD Routine thoracentesis in addition to standard medical therapy showed no significant benefit! https://t.co/LXOQinJov8
Finally! TAP-IT putting this long-standing, overused procedure under the spotlight. I’ve been side-eyeing it for years—and staying clear. Glad to see the data catching up. Kudos to authors. #signeglargaard #CardioTwitter #EvidenceMatters https://t.co/rn6p6KZvuN https://t.co/AlgDO19XUg
@hvanspall There is one- TAP-IT recently published trial, with DAOH as a pre-specified pEP—thoughtfully highlighted in this week’s TWIC by @drjohnm - as always definitely worth listening
https://t.co/aO3lQ8xZA4
Thoracentesis added to standard therapy for acute heart failure showed no significant improvement in hospital-free days or mortality. by Glargaard S, Hartvig Thomsen J (...) Thune JJ et 16 al. in Circulation https://t.co/4hRSG0OeDV #MedX #MedResearch
RT @qqqjunpei: Circulation 2025/4/1
急性心不全、左室駆出率≤45%、および相当量の胸水(胸腔穿刺は可能だが片胸郭の3分の2未満)のある患者の場合、治療的胸腔穿刺を追加しても入院期間の短縮やその後90日間の予後の良好にはつながらなかったというRCT。確かにあんまりやったことない。 https://t.co/8SCzQbZlS6
RT @CircAHA: Routine thoracentesis in acute HF with pleural effusion doesn’t improve DAOH, mortality, or shorten hospital stay @mortschou…
RT @CircAHA: Routine thoracentesis in acute HF with pleural effusion doesn’t improve DAOH, mortality, or shorten hospital stay @mortschou…
RT @CircAHA: Routine thoracentesis in acute HF with pleural effusion doesn’t improve DAOH, mortality, or shorten hospital stay @mortschou…
RT @CircAHA: Routine thoracentesis in acute HF with pleural effusion doesn’t improve DAOH, mortality, or shorten hospital stay @mortschou…
RT @CircAHA: Routine thoracentesis in acute HF with pleural effusion doesn’t improve DAOH, mortality, or shorten hospital stay @mortschou…
A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure thoracentesis in addition to standard medical therapy did not increase days alive out of the hospital for 90 days, all-cause mortality, or duration of index admission https://t.co/EKJO6CKGln https://t.co/QrfwvjoSKk
RT @CircAHA: Routine thoracentesis in acute HF with pleural effusion doesn’t improve DAOH, mortality, or shorten hospital stay @mortschou…
A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure | Circulation https://t.co/9HhUKsTQqK This study is very welcome, it suggests a rather limited role, if any, for routine thoracentesis in heart failure
RT @CircAHA: Routine thoracentesis in acute HF with pleural effusion doesn’t improve DAOH, mortality, or shorten hospital stay @mortschou…
RT @CircAHA: Routine thoracentesis in acute HF with pleural effusion doesn’t improve DAOH, mortality, or shorten hospital stay @mortschou…
Routine thoracentesis in acute HF with pleural effusion doesn’t improve DAOH, mortality, or shorten hospital stay @mortschou @signeglargaard https://t.co/p9RC3TwPfM https://t.co/FIMxGmngEH
RT @drjohnm: https://t.co/QHLboxkGpQ Highest congratulations to the authors, Dr. Signe Glargaard et al
TAP-IT Trial: In acute HF (LVEF ≤45%) with pleural effusion <⅔ hemithorax, routine thoracentesis did not improve 90-day outcomes, QoL, or LOS vs standard care. Decongestion with GDMT remains key. #MedTwitter #FOAMed #MedEd #CardioTwitter https://t.co/Sd1W3Rrmnc https://t.co/J30ckbDlWI
https://t.co/yJdIPPXd5t
RT @drjohnm: https://t.co/QHLboxkGpQ Highest congratulations to the authors, Dr. Signe Glargaard et al
A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure | Circulation https://t.co/roDRKLhNez
RT @drjohnm: https://t.co/QHLboxkGpQ Highest congratulations to the authors, Dr. Signe Glargaard et al
RT @qqqjunpei: Circulation 2025/4/1
RT @drjohnm: https://t.co/QHLboxkGpQ Highest congratulations to the authors, Dr. Signe Glargaard et al
RT @ykano21: 心不全の胸水、利尿薬でゆっくり引くなんて焦ったいことせずに、抜いちゃえばいいぢゃん、っていうRCT。こういう素朴な臨床疑問好きです。結果は利尿薬のみと変わらずでプラクティスは変えず。でも心不全の胸水にドレーン入れているのをバイト先で見たことはある。。…
RT @ykano21: 心不全の胸水、利尿薬でゆっくり引くなんて焦ったいことせずに、抜いちゃえばいいぢゃん、っていうRCT。こういう素朴な臨床疑問好きです。結果は利尿薬のみと変わらずでプラクティスは変えず。でも心不全の胸水にドレーン入れているのをバイト先で見たことはある。。…
RT @qqqjunpei: Circulation 2025/4/1
RT @ykano21: 心不全の胸水、利尿薬でゆっくり引くなんて焦ったいことせずに、抜いちゃえばいいぢゃん、っていうRCT。こういう素朴な臨床疑問好きです。結果は利尿薬のみと変わらずでプラクティスは変えず。でも心不全の胸水にドレーン入れているのをバイト先で見たことはある。。…
RT @drjohnm: https://t.co/QHLboxkGpQ Highest congratulations to the authors, Dr. Signe Glargaard et al
RT @ykano21: 心不全の胸水、利尿薬でゆっくり引くなんて焦ったいことせずに、抜いちゃえばいいぢゃん、っていうRCT。こういう素朴な臨床疑問好きです。結果は利尿薬のみと変わらずでプラクティスは変えず。でも心不全の胸水にドレーン入れているのをバイト先で見たことはある。。…
RT @ykano21: 心不全の胸水、利尿薬でゆっくり引くなんて焦ったいことせずに、抜いちゃえばいいぢゃん、っていうRCT。こういう素朴な臨床疑問好きです。結果は利尿薬のみと変わらずでプラクティスは変えず。でも心不全の胸水にドレーン入れているのをバイト先で見たことはある。。…
RT @ykano21: 心不全の胸水、利尿薬でゆっくり引くなんて焦ったいことせずに、抜いちゃえばいいぢゃん、っていうRCT。こういう素朴な臨床疑問好きです。結果は利尿薬のみと変わらずでプラクティスは変えず。でも心不全の胸水にドレーン入れているのをバイト先で見たことはある。。…
RT @drjohnm: https://t.co/QHLboxkGpQ Highest congratulations to the authors, Dr. Signe Glargaard et al
RT @drjohnm: https://t.co/QHLboxkGpQ Highest congratulations to the authors, Dr. Signe Glargaard et al
RT @ykano21: 心不全の胸水、利尿薬でゆっくり引くなんて焦ったいことせずに、抜いちゃえばいいぢゃん、っていうRCT。こういう素朴な臨床疑問好きです。結果は利尿薬のみと変わらずでプラクティスは変えず。でも心不全の胸水にドレーン入れているのをバイト先で見たことはある。。…
RT @drjohnm: https://t.co/QHLboxkGpQ Highest congratulations to the authors, Dr. Signe Glargaard et al
https://t.co/QHLboxkGpQ Highest congratulations to the authors, Dr. Signe Glargaard et al
RT @qqqjunpei: Circulation 2025/4/1
RT @qqqjunpei: Circulation 2025/4/1
RT @qqqjunpei: Circulation 2025/4/1
RT @qqqjunpei: Circulation 2025/4/1
RT @qqqjunpei: Circulation 2025/4/1
RT @qqqjunpei: Circulation 2025/4/1
RT @qqqjunpei: Circulation 2025/4/1
RT @qqqjunpei: Circulation 2025/4/1
RT @qqqjunpei: Circulation 2025/4/1
A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure. www.ahajournals.org/doi/10.1161/... @ahascience.bsky.social @ahajournals.bsky.social #CardioSky #MedSky #AHAJournals #HeartFailure
心不全の胸水、利尿薬でゆっくり引くなんて焦ったいことせずに、抜いちゃえばいいぢゃん、っていうRCT。こういう素朴な臨床疑問好きです。結果は利尿薬のみと変わらずでプラクティスは変えず。でも心不全の胸水にドレーン入れているのをバイト先で見たことはある。。 https://t.co/oRar4pAcKP
RT @qqqjunpei: Circulation 2025/4/1
RT @qqqjunpei: Circulation 2025/4/1
RT @qqqjunpei: Circulation 2025/4/1
RT @qqqjunpei: Circulation 2025/4/1
Circulation 2025/4/1
A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure https://t.co/RihuWumTA7
RT @piccoloraf: TAP-IT: in a small RCT, a strategy of upfront routine thoracentesis did not improve clinical outcomes & QoL among pts with…
A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure | Circulation https://t.co/9jDcZl9OwA
RT @piccoloraf: TAP-IT: in a small RCT, a strategy of upfront routine thoracentesis did not improve clinical outcomes & QoL among pts with…
TAP-IT: in a small RCT, a strategy of upfront routine thoracentesis did not improve clinical outcomes & QoL among pts with acute HF and pleural effusion. @PCRonline @mmamas1973 @djc795 @drjohnm @cpgale3 @gcfmd #CardioX https://t.co/vkyjDAt8IU https://t.co/H0JIYmxAXt